A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
The DOI matches its Crossref record.
Abstract
Introduction: Myeloid cells express PD1 and CTL-A. The expression of these molecules is activated by treatment with a hypomethylating agent (HMA) both in cell lines and patient samples. We hypothesized that treatment of patients with MDS with immune checkpoint inhibitors (ICPI) blocking CTLA or PD1 with or without azacitidine could have activity both in front line and relapsed MDS. Methods: To study this, we designed a basket exploratory phase 2 trial of ICPI in MDS. Patients with MDS age 18 or older with adequate renal and hepatic function without history of autoimmune disorders were eligible. Patients were divided into front-line and HMA-failure cohorts. Front-line patients were treated in two different cohorts: AZA + nivolumab (Nivo) and AZA + ipilimumab (Ipi). Patients in the HMA failure cohort were treated in 2 cohorts: single agent Nivo and single agent Ipi. In the HMA failure cohort, patients were first treated with single agent ICPI, and after 6 cycles (or earlier if evidence of progression), the use of azacitidine was allowed to test the concept of re-sensitization. If there was no response, azacitidine was added back. Cohorts could enroll a max of 20 patients with stopping rules for toxicity and response. Nivolumab was administered at a dose of 3 mg/kg on days 1 and 15 every 4-week cycle and ipilimumab at 3 mg/kg on day 1 every 3-week cycle. Azacitidine was used at the standard dose. When combined with azacitidine, nivolumab was administered on days 6 and 20 every 4-week cycle and ipilimumab on day 6 every 4-week cycle. Results: From 11/12/2015 to 8/10/2017, 76 patients were treated. 41 pts (54%) on front-line cohort and 35 (46%) on HMA failure. The median age was 71 years (range, 39.5-85.7). IPSS risk was Low 3 patients (4%), INT-1 30 patients (40%), INT-2 28 patients (37%), High 11 (15%), and unknown 4 (5%). 29 patients (38%) had complex karyotype; 17 patients (22%), diploid; 25 (33%), other; 5 (7%), insufficient metaphases. Next generation sequencing on whole bone marrow extracted DNA was performed using a 28 or 81-gene panel. Distribution of mutations was as follows: ABL, 4 (5%); ASXL1, 17 (22%); BRAF, 2 (3%); CBL 2 (3%); DNMT3A, 7 (9%); IDH1, 2 (3%); IDH2, 4 (5%); IKZF2, 1 (1%); JAK2, 1 (1%); KIT, 2 (3%); NPM1, 1 (1%); RAS, 14 (18%); RUNX1, 15 (20%); 1, SF3B1, 1 (3%); SRSF2, 2 (3%); TET2, 12 (16%); TP53, 22 (29%); U2AF1, 1 (1%). Median number of marrow blasts was 7% (range, 0-18). Median WBC and platelets was 2.9 (range, 0.5-48.2) and 46 (range, 2-319), respectively. 20 patients were treated with AZA+Nivo, 21 with AZA+Ipi, 15 with Nivo, and 20 with Ipi. In summary, toxicities were as follows; skin rash, 26 (11%); fatigue, 22 (9%); pain, 16 (7%); infection, 14 (6%); febrile neutropenia, 13 (5%); pruritus, 14 (6%); diarrhea, 11 (5%); constipation, 9 (4%); nausea, 10 (4%), ALT elevations, 8 (3%); anorexia, 7 (3%); cough, 7 (3%). Early mortality was observed in 1 patient (1%). Overall response was observed in 15/20 (75%), 15/21 (71%), 2/15 (13%), and 7/20 (35%) of pts treated with AZA+Nivo, AZA+Ipi, Nivo, and Ipi, respectively; CR/CRp was observed in 10/20 (50%), 8/21 (38%), 0 (0%), and 3 (15%) in pts treated with AZA+Nivo, AZA+Ipi, Nivo, and Ipi, respectively. In addition, clearance of detectable mutations through the course of therapy was observed in 3 (15%) pts treated with Ipi, 4 (20%) with AZA+Nivo and 3 (14%) with AZA+Ipi. The median cycle received was 4 cycles (range, 1-25). Among 37 patients with response, the median cycle to response was 3 cycles (range, 1-10). With a median follow up of 20 months, the median overall survival were 12 months, not reached, 8 months, and 8 months with AZA+Nivo, AZA+Ipi, Nivo, and Ipi, respectively (Figure 1A; Figure 1B). Event-free survival were 10 months, not reached, 7 months, 6 months with AZA+Nivo, AZA+Ipi, Nivo, and Ipi, respectively. One-year survival rates were 50%, 68%, 25%, and 45%, respectively. The median event-free survival were 16 months and 7 months in the frontline and HMA failure cohort, respectively (p=0.096); the median overall survival were 17 months and 8 months in the frontline and HMA failure cohort, respectively (p=0.030). Conclusion: The incorporation of ICPI is feasible in MDS. These agents have significant activity as single agents and in combination in MDS with an acceptable toxicity profile and significant response and survival outcomes, particularly with ipilimumab. Further randomized studies are needed. Disclosures: Sasaki: Otsuka Pharmaceutical: Honoraria. Daver:Novartis: Research Funding; ARIAD: Research Funding; Karyopharm: Consultancy; Kiromic: Research Funding; Sunesis: Consultancy; Otsuka: Consultancy; Incyte: Consultancy; BMS: Research Funding; Daiichi-Sankyo: Research Funding; Alexion: Consultancy; Pfizer: Research Funding; Incyte: Research Funding; Novartis: Consultancy; ImmunoGen: Consultancy; Pfizer: Consultancy; Sunesis: Research Funding; Karyopharm: Research Funding. DiNardo:Medimmune: Honoraria; Karyopharm: Honoraria; Celgene: Honoraria; Abbvie: Honoraria; Agios: Consultancy; Bayer: Honoraria. Ravandi:Xencor: Research Funding; Bristol-Myers Squibb: Research Funding; Astellas Pharmaceuticals: Consultancy, Honoraria; Sunesis: Honoraria; Seattle Genetics: Research Funding; Macrogenix: Honoraria, Research Funding; Sunesis: Honoraria; Macrogenix: Honoraria, Research Funding; Orsenix: Honoraria; Jazz: Honoraria; Abbvie: Research Funding; Orsenix: Honoraria; Seattle Genetics: Research Funding; Amgen: Honoraria, Research Funding, Speakers Bureau; Astellas Pharmaceuticals: Consultancy, Honoraria; Jazz: Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Abbvie: Research Funding; Bristol-Myers Squibb: Research Funding; Xencor: Research Funding. Bose:Astellas Pharmaceuticals: Research Funding; CTI BioPharma: Research Funding; Blueprint Medicines Corporation: Research Funding; Celgene Corporation: Honoraria, Research Funding; Pfizer, Inc.: Research Funding; Incyte Corporation: Honoraria, Research Funding; Constellation Pharmaceuticals: Research Funding. Pemmaraju:abbvie: Research Funding; Affymetrix: Research Funding; SagerStrong Foundation: Research Funding; daiichi sankyo: Research Funding; novartis: Research Funding; plexxikon: Research Funding; samus: Research Funding; stemline: Consultancy, Honoraria, Research Funding; celgene: Consultancy, Honoraria; cellectis: Research Funding. Cortes:novartis: Research Funding. Kadia:Takeda: Consultancy; Novartis: Consultancy; Pfizer: Consultancy, Research Funding; Abbvie: Consultancy; Amgen: Consultancy, Research Funding; Celgene: Research Funding; Takeda: Consultancy; Celgene: Research Funding; Pfizer: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Abbvie: Consultancy; BMS: Research Funding; BMS: Research Funding; Novartis: Consultancy. Konopleva:Stemline Therapeutics: Research Funding. Colla:Abbvie: Research Funding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood · doi:10.1182/blood.2020006158 · Cited by 196
Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01794 · Cited by 188
Self-citationCurrent status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
Hunter, A. M., Komrokji, R. S., Yun, S., Al Ali, N., Chan, O., Song, J., Hussaini, M., Talati, C., Sweet, K. L., Lancet, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003508 · Cited by 76
Current and emerging strategies for management of myelodysplastic syndromes
Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70
Metadata
- Authors
- Garcia-Manero, G., Sasaki, K., Montalban-Bravo, G., Daver, N. G., Jabbour, E. J., Alvarado, Y., DiNardo, C. D., Ravandi, F., Borthakur, G., Bose, P., Pemmaraju, N., Naqvi, K., Cortes, J. E., Kadia, T. M., Konopleva, M. Y., Colla, S., Yang, H., Rausch, C. R., Gasior, Y., Bueso-Ramos, C. E., Kanagal-Shamanna, R., Patel, K. P., & Kantarjian, H. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-11-29
- Volume
- 132
- Issue
- Supplement 1
- Pages
- 465-465
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2906720786
- Cited by
- 68
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). https://app.cochat.ai/papers/10.1182/blood-2018-99-119424
- The paper
- Garcia-Manero, G., Sasaki, K., Montalban-Bravo, G., Daver, N. G., Jabbour, E. J., Alvarado, Y., DiNardo, C. D., Ravandi, F., Borthakur, G., Bose, P., Pemmaraju, N., Naqvi, K., Cortes, J. E., Kadia, T. M., Konopleva, M. Y., Colla, S., Yang, H., Rausch, C. R., Gasior, Y., . . . Kantarjian, H. M. (2018). A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood. https://doi.org/10.1182/blood-2018-99-119424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.